The Gill Center’s Lymphoma Program features a team of pediatric oncologists experienced in caring for children with any type of childhood Hodgkin and Non-Hodgkin lymphoma. These experts have access to regional, national and international clinical trials offering the latest treatment therapies – tailoring the therapy to provide the greatest chance to cure each patient.
What We Treat
We treat all forms of pediatric Hodgkin and Non-Hodgkin lymphoma. As a group, lymphomas represent the third most common childhood cancer. We routinely treat Hodgkin lymphoma, which is the most common cancer in 15- to 19-year-olds, accounting for about 1,200 of the 1,700 cases of childhood lymphoma in the U.S. each year.
Non-Hodgkin lymphomas are a diverse group of malignancies, the more common of which are Burkitt lymphoma, diffuse large B cell lymphoma, and anaplastic large cell lymphoma. The breadth and depth of expertise within our program also allows us to treat patients with even the rarest Non-Hodgkin lymphomas. Over the past few years, we have developed treatment plans for adolescents with primary central nervous system lymphoma, follicular lymphoma, blastic plasmacytoid dendritic cell neoplasm, post- transplant lymphoproliferative diseases and others.
- Between 25 and 30 newly diagnosed patients each year
- Experience in every form of childhood Hodgkin and non-Hodgkin lymphoma, from the most common to the rarest
- Opportunities to receive the most advanced therapies for childhood lymphoma through participation in clinical research
Beyond Children's Oncology Group clinical trials, we conduct our own research. Current projects include:
- Early diagnosis of invasive fungal disease and fungal prophylaxis in children with acute lymphoblastic and myelogenous leukemia
- Identifying factors that predict risk for serious infection in children with leukemia
- Early phase clinical trials employing new therapeutic agents to eradicate leukemia cells
- Laboratory research efforts at UT Southwestern to understand the biology of stem cells from which leukemia begins